NEW YORK and SHANGHAI, Feb. 26, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. CBMG ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on Friday, February 28, 2020.
The Company will host a conference call and webcast with the investment community on Friday, February 28th at 4:30 p.m. Eastern Time, featuring remarks by Tony Liu, Executive Director, CEO and CFO of CBMG.
What: | Cellular Biomedicine Fourth Quarter and Full Year 2019 Results Conference Call |
Date: | Friday, February 28, 2020 |
Time: | 4:30 p.m. Eastern Time |
Live Call: | Toll-Free: 1-877-423-9813 International: 1-201-689-8573 |
Webcast: | |
Replay: | Toll-Free: 1-844-512-2921 International: 1-412-317-6671 Conference ID: 13699688 (Available approximately two hours after the completion of the live call until 11:59 p.m. ET on March 13, 2020) |
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. is a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases. For more information, please visit https://www.cellbiomedgroup.com/.
For more information, please contact:
Company Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com
Investor Contact:
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1254 / 212-896-1267
Email: cellbiomed@kcsa.com
SOURCE Cellular Biomedicine Group, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.